RESUMEN
Hemibody irradiation (HBI) is a radiation therapy technique that involves treating one-half of the patient's skeletal system in a single radiation field. It is mostly given as upper hemibody irradiation (UHBI), lower hemibody irradiation (LHBI), or sequential UHBI and LHBI. It is used to treat extensive bone metastases from solid tumors. It was primarily utilized in the 1980s and 1990s and has since fallen out of favor. However, it is a potentially cost-effective treatment for widespread bone metastases. To determine its efficacy, we performed a meta-analysis of all available published articles on the efficacy of HBI to relieve pain from bone metastases. Twenty-seven articles involving 1318 patients were identified and analyzed. Our findings show that 80% of the patients had complete or partial pain relief and 29% had complete pain relief. The trials were of poor quality, but the results showed minimal heterogeneity in the response rates. These response rates are consistent with those seen with focal irradiation of bone metastases and for radionuclide treatment of bone metastases. The toxicity of the treatments decreased when delivered with modern treatment techniques. In light of this, we propose that this technique warrants re-evaluation with modern treatment methods.
RESUMEN
PURPOSE: To dynamically detect and characterize 18F-fluorodeoxyglucose (FDG) dose infiltrations and evaluate their effects on positron emission tomography (PET) standardized uptake values (SUV) at the injection site and in control tissue. METHODS: Investigational gamma scintillation sensors were topically applied to patients with locally advanced breast cancer scheduled to undergo limited whole-body FDG-PET as part of an ongoing clinical study. Relative to the affected breast, sensors were placed on the contralateral injection arm and ipsilateral control arm during the resting uptake phase prior to each patient's PET scan. Time-activity curves (TACs) from the sensors were integrated at varying intervals (0-10, 0-20, 0-30, 0-40, and 30-40 min) post-FDG and the resulting areas under the curve (AUCs) were compared to SUVs obtained from PET. RESULTS: In cases of infiltration, observed in three sensor recordings (30 %), the injection arm TAC shape varied depending on the extent and severity of infiltration. In two of these cases, TAC characteristics suggested the infiltration was partially resolving prior to image acquisition, although it was still apparent on subsequent PET. Areas under the TAC 0-10 and 0-20 min post-FDG were significantly different in infiltrated versus non-infiltrated cases (Mann-Whitney, p < 0.05). When normalized to control, all TAC integration intervals from the injection arm were significantly correlated with SUVpeak and SUVmax measured over the infiltration site (Spearman ρ ≥ 0.77, p < 0.05). Receiver operating characteristic (ROC) analyses, testing the ability of the first 10 min of post-FDG sensor data to predict infiltration visibility on the ensuing PET, yielded an area under the ROC curve of 0.92. CONCLUSIONS: Topical sensors applied near the injection site provide dynamic information from the time of FDG administration through the uptake period and may be useful in detecting infiltrations regardless of PET image field of view. This dynamic information may also complement the static PET image to better characterize the true extent of infiltrations.
Asunto(s)
Neoplasias de la Mama/metabolismo , Fluorodesoxiglucosa F18/administración & dosificación , Fluorodesoxiglucosa F18/farmacocinética , Radiofármacos/farmacocinética , Conteo por Cintilación/instrumentación , Absorción Fisiológica , Neoplasias de la Mama/diagnóstico por imagen , Sistemas de Computación , Monitoreo de Drogas/instrumentación , Diseño de Equipo , Análisis de Falla de Equipo , Femenino , Humanos , Inyecciones , Tasa de Depuración Metabólica , Dosis de Radiación , Radiofármacos/administración & dosificación , Reproducibilidad de los Resultados , Conteo por Cintilación/métodos , Sensibilidad y Especificidad , Distribución TisularRESUMEN
PURPOSE: The Radiation Therapy Oncology Group (RTOG) conducted a randomized, placebo-controlled trial evaluating the efficacy of GM-CSF in reducing mucosal injury and symptom burden from curative radiotherapy for head and neck (H&N) cancer. METHODS: Eligible patients with H&N cancer receiving radiation encompassing ≥50 % of the oral cavity or oropharynx received subcutaneous GM-CSF or placebo. Quality of life (QoL) was assessed using the RTOG-modified University of Washington H&N Symptom Questionnaire at baseline 4, 13, 26, and 48 weeks from radiation initiation. RESULTS: Of 125 eligible patients, 114 were evaluable for QoL (58 GM-CSF, 56 placebo). Patient demographics, clinical characteristics, and baseline symptom scores were well balanced between the treatment arms. At the end of the acute period (13 weeks), patients in both arms reported negative change in total symptom score indicating increase in symptom burden relative to baseline (mean -18.4 GM-CSF, -20.8 placebo). There was no difference in change in total symptom score (p > 0.05) or change in mucous, pain, eating, or activity domain scores (p > 0.01) between patients in the GM-CSF and placebo arms. Analysis limited to patients treated per protocol or with an acceptable protocol deviation also found no difference in change in total symptom score (p > 0.05) or change in domain scores (p > 0.01) between treatment arms. Provider assessment of acute mucositis during treatment did not correlate with patient-reported mucous domain and total symptom scores (p > 0.05). CONCLUSION: GM-CSF administered concurrently during head and neck radiation does not appear to significantly improve patient-reported QoL symptom burden.
Asunto(s)
Factor Estimulante de Colonias de Granulocitos y Macrófagos/uso terapéutico , Neoplasias de Cabeza y Cuello/psicología , Evaluación del Resultado de la Atención al Paciente , Calidad de Vida , Canadá , Costo de Enfermedad , Método Doble Ciego , Femenino , Factor Estimulante de Colonias de Granulocitos y Macrófagos/efectos adversos , Neoplasias de Cabeza y Cuello/radioterapia , Humanos , Masculino , Persona de Mediana Edad , Traumatismos por Radiación/prevención & control , Protectores contra Radiación/efectos adversos , Protectores contra Radiación/uso terapéutico , Factores Socioeconómicos , Encuestas y Cuestionarios , Estados UnidosRESUMEN
Background: The objective of this study was to validate a simple predictive model for survival of patients with advanced cancer. Methods: Previous studies with training and validation datasets developed a model predicting survival of patients referred for palliative radiotherapy using three readily available factors: primary cancer site, site of metastases and Karnofsky performance score (KPS). This predictive model was used in the current study, where each factor was assigned a value proportional to its prognostic weight and the sum of the weighted scores for each patient was survival prediction score (SPS). Patients were also classified according to their number of risk factors (NRF). Three risk groups were established. The Radiation Therapy and Oncology Group (RTOG) 9714 data was used to provide an additional external validation set comprised of patients treated among multiple institutions with appropriate statistical tests. Results: The RTOG external validation set comprised of 908 patients treated at 66 different radiation facilities from 1998 to 2002. The SPS method classified all patients into the low-risk group. Based on the NRF, two distinct risk groups with significantly different survival estimates were identified. The ability to predict survival was similar to that of the training and previous validation datasets for both the SPS and NRF methods. Conclusions: The three variable NRF model is preferred because of its relative simplicity.
RESUMEN
PURPOSE: To explore the relationships (clusters) among the functional interference items in the Brief Pain Inventory (BPI) in patients with bone metastases. METHODS: Patients enrolled in the Radiation Therapy Oncology Group (RTOG) 9714 bone metastases study were eligible. Patients were assessed at baseline and 4, 8, and 12 weeks after randomization for the palliative radiotherapy with the BPI, which consists of seven functional items: general activity, mood, walking ability, normal work, relations with others, sleep, and enjoyment of life. Principal component analysis with varimax rotation was used to determine the clusters between the functional items at baseline and the follow-up. Cronbach's alpha was used to determine the consistency and reliability of each cluster at baseline and follow-up. RESULTS: There were 448 male and 461 female patients, with a median age of 67 years. There were two functional interference clusters at baseline, which accounted for 71% of the total variance. The first cluster (physical interference) included normal work and walking ability, which accounted for 58% of the total variance. The second cluster (psychosocial interference) included relations with others and sleep, which accounted for 13% of the total variance. The Cronbach's alpha statistics were 0.83 and 0.80, respectively. The functional clusters changed at week 12 in responders but persisted through week 12 in nonresponders. CONCLUSION: Palliative radiotherapy is effective in reducing bone pain. Functional interference component clusters exist in patients treated for bone metastases. These clusters changed over time in this study, possibly attributable to treatment. Further research is needed to examine these effects.
Asunto(s)
Neoplasias Óseas/radioterapia , Neoplasias Óseas/secundario , Dimensión del Dolor/métodos , Análisis de Componente Principal , Calidad de Vida , Actividades Cotidianas , Adulto , Afecto , Anciano , Anciano de 80 o más Años , Neoplasias Óseas/psicología , Femenino , Humanos , Relaciones Interpersonales , Estado de Ejecución de Karnofsky , Masculino , Persona de Mediana Edad , Dosificación Radioterapéutica , Reproducibilidad de los Resultados , Sueño , CaminataRESUMEN
To determine which of the previously proposed functional interference cluster models is most appropriate in patients with bone metastases and to determine if the cluster structures identified at baseline differed between responders and non-responders following palliative radiotherapy. METHODS: The confirmatory test data set consists of breast and prostate cancer patients treated with palliative radiotherapy between May 2003 to January 2007. Worst pain and functional interference scores were assessed using Brief Pain Inventory at baseline, 4, 8 and 12 weeks post radiation treatment. The baseline cluster structure of the confirmatory dataset was compared to each of the previously proposed baseline cluster models. Maximum likelihood CFA was used to account for possible correlation amongst the factor components. A MIMIC model was used to determine the invariance of the cluster models between responders and non-responders during follow-up. RESULTS: A total of 169 eligible patients were analysed. There were 91 male and 78 female patients with a median age of 68 years. The median KPS was 70. A single 8 Gy and 20 Gy in 5 fractions were used in 97% of all analysed patients. The RTOG model, in which relationships with others and sleep comprised the mood-related interference cluster and walking ability and normal work comprised the physical-interference cluster, provides the best fit for the sample data. The follow-up cluster structure is not similar across the responder groups indicating that cluster structures shift following radiation treatment, as evidenced by pain response. CONCLUSION: Although differing slightly this analysis confirms pretreatment symptom clusters exist for patients with bone metastases from breast or prostate cancer based on the RTOG 9714 data. This could help formulate symptom management interventions at initial diagnosis. Symptom clusters dissolve or change after treatment which may be a function of the treatment or population and requires further study.
RESUMEN
The Dose Verification System (DVS) is the first implantable radiation dosimeter designed for in situ measurement of dose delivered to the tissue being irradiated. The success of radiation therapy is predicated on maximizing tumor cell death and minimizing normal tissue toxicity. Tumor control increases with the delivery of appropriate radiation doses to the target area. These doses have been determined from in vitro and animal studies, which generated specific dose-response data. However, there has not been a practical system available to ensure that the appropriate dose was being delivered in situ to monitor the daily patient dose during radiation therapy. Studies have shown that dose variations can occur. Recently completed pivotal clinical studies using the DVS found a greater than 7% (positive or negative) change in cumulative dose in seven out of 36 (19%) breast cancer patients; and six out of 29 (21%) and eight out of 19 (42%) patients during large-field and boost irradiation of the prostate. The device is an important step to enable physicians to expand the concept of individualization of therapy.
Asunto(s)
Neoplasias de la Mama/radioterapia , Neoplasias de la Próstata/radioterapia , Radiometría/instrumentación , Radioterapia Asistida por Computador/instrumentación , Animales , Análisis Costo-Beneficio , Relación Dosis-Respuesta en la Radiación , Diseño de Equipo , Femenino , Humanos , Masculino , Radiometría/economía , Radiometría/normas , Dosificación Radioterapéutica , Radioterapia Asistida por Computador/economía , Radioterapia Asistida por Computador/normas , Radioterapia de Intensidad ModuladaRESUMEN
PURPOSE: Report the results of using a permanently implantable dosimeter in radiation therapy: determine specific adverse events, degree of migration, and acquire dose measurements during treatment to determine difference between expected and measured dose. METHODS AND MATERIALS: The Dose Verification System is a wireless, permanently implantable metal-oxide semiconductor field-effect transistor dosimeter using a bidirectional antenna for power and data transfer. The study cohort includes 36 breast (33 patients received two devices) and 29 prostate (21 patients received two devices) cancer patients. A total of 1,783 and 1,749 daily dose measurements were obtained on breast and prostate patients, respectively. The measurements were compared with the planned expected dose. Biweekly computed tomography scans were obtained to evaluate migration and the National Cancer Institute's Common Toxicity Criteria, version 3, was used to evaluate adverse events. RESULTS: Only Grade I/II adverse events of pain and bleeding were noted. There were only four instances of dosimeter migration of >5 mm from known factors. A deviation of > or =7% in cumulative dose was noted in 7 of 36 (19%) for breast cancer patients. In prostate cancer patients, a > or =7% deviation was noted in 6 of 29 (21%) and 8 of 19 (42%) during initial and boost irradiation, respectively. The two patterns of dose deviation were random and systematic. Some causes for these differences could involve organ movement, patient movement, or treatment plan considerations. CONCLUSIONS: The Dose Verification System was not associated with significant adverse events or migration. The dosimeter can measure dose in situ on a daily basis. The accuracy and utility of the dose verification system complements current image-guided radiation therapy and intensity-modulated radiation therapy techniques.
Asunto(s)
Neoplasias de la Mama/radioterapia , Neoplasias de la Próstata/radioterapia , Neoplasias de la Mama/diagnóstico por imagen , Diseño de Equipo , Femenino , Migración de Cuerpo Extraño/diagnóstico por imagen , Humanos , Masculino , Mamografía , Movimiento , Proyectos Piloto , Neoplasias de la Próstata/diagnóstico por imagen , Prótesis e Implantes/efectos adversos , Radiometría/instrumentación , Radiometría/métodos , Dosificación RadioterapéuticaRESUMEN
PURPOSE: To determine if physician prediction of survival duration (PSD) is accurate for patients with metastatic breast or prostate cancer. METHODS: Radiation Therapy Oncology Group 9714 (RTOG 9714) was a randomized comparison of radiotherapy schedules for treatment of bone metastases. The treating physician assigned a baseline Karnofsky Performance Score (KPS) and predicted survival duration at study entry. Patients completed the Functional Assessment of Cancer Therapy (FACT). These three were compared to actual survival time. RESULTS: Eight hundred ninety-eight patients were eligible and analyzable. Actual median survival was 9.3 months. The median PSD was 12 months. PSD, KPS, and FACT were all moderately correlated with actual survival. Patients with higher KPS had a longer survival time (882 patients, Spearman's rho = 0.259, p < 0.0001). The median survival of the 618 expired patients is 6.5 months (PSD was 12 months). The PSD was within 1 month of actual survival in 61 (10%), with 177 (29%) patients surviving more than 1 month longer than predicted and 375 (61%) surviving more than 1 month less than predicted. A univariate analysis of actual overall survival was performed, dividing the PSD into 4 groups. For predicted survivals of 6 months or less, less than 6 to less than 12 months, 12 months, and more than 12 months, median actual survivals were 7.0, 7.2, 9.7. and 13.5 months (p < 0.0001). CONCLUSIONS: KPS, FACT scores, and PSD all are correlated with actual survival. Physicians on this study were able to predict which patients would have longer survival times, although prediction of survival was optimistic compared to actual survival by an average of 3 months.
Asunto(s)
Metástasis de la Neoplasia , Médicos , Análisis de Supervivencia , Adulto , Anciano , Anciano de 80 o más Años , Neoplasias de la Mama/mortalidad , Neoplasias de la Mama/fisiopatología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Pronóstico , Neoplasias de la Próstata/mortalidad , Neoplasias de la Próstata/fisiopatología , Ensayos Clínicos Controlados Aleatorios como Asunto , Reproducibilidad de los ResultadosRESUMEN
PURPOSE: To perform a comparison of the daily measured dose at depth in tissue with the predicted dose values from treatment plans for 29 prostate cancer patients involved in a clinical trial. METHODS AND MATERIALS: Patients from three clinical sites were implanted with one or two dosimeters in or near the prostatic capsule. The implantable device, known as the DVS, is based on a metal-oxide-semiconductor field effect transistor (MOSFET) detector. A portable telemetric readout system couples to the dosimeter antenna (visible on kilovoltage, computed tomography, and ultrasonography) for data transfer. The predicted dose values were determined by the location of the MOSFET on the treatment planning computed tomography scan. Serial computed tomography images were taken every 2 weeks to evaluate any migration of the device. The clinical protocol did not permit alteration of the treatment parameters using the dosimeter readings. For some patients, one of several image-guided radiotherapy (RT) modalities was used for target localization. RESULTS: The evaluation of dose discrepancy showed that in many patients the standard deviation exceeded the previous values obtained for the dosimeter in a phantom. In some patients, the cumulative dose disagreed with the planned dose by > or =5%. The data presented suggest that an implantable dosimeter can help identify dose discrepancies (random or systematic) for patients treated with external beam RT and could be used as a daily treatment verification tool for image-guided RT and adaptive RT. CONCLUSION: The results of our study have shown that knowledge of the dose delivered per fraction can potentially prevent over- or under-dosage to the treatment area and increase the accuracy of RT. The implantable dosimeter could also be used as a localizer for image-guided RT.
Asunto(s)
Neoplasias de la Próstata/radioterapia , Dosificación Radioterapéutica , Humanos , Masculino , Fenómenos Físicos , Física , Prótesis e Implantes , Radiometría/instrumentación , Planificación de la Radioterapia Asistida por ComputadorRESUMEN
OBJECTIVE: The purpose of this study was to determine if radiographic response correlates with survival for patients treated patients with malignant gliomas treated on Radiation Therapy Oncology Group (RTOG) protocol 90-06. This study compared patients treated with hyperfractionated radiation and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) to standard fractionation and BCNU. METHODS: There were 453 patients evaluable. Histology included anaplastic astrocytoma (60) (AA), and glioblastoma multiforme (312) (GBM). All scans were forwarded to the RTOG central office and evaluated by a single reviewer without knowledge of outcome. Response at 4 months post initiation of therapy was evaluated by computed tomography or magnetic resonance image and compared with overall survival. RESULTS: For patients with no tumor on the 4 month scan the median survival was 20.3 months and the 2 year survival 43%. Patients with partial or minor response had a median survival of 18.1 and 14.2 months and 2 year survival of 37% and 29%. Patients with progression had a median survival of 8.6 months and 2 year survival of 10%. CONCLUSIONS: Response rates were similar in both arms.
Asunto(s)
Glioma/diagnóstico por imagen , Glioma/patología , Antineoplásicos Alquilantes/uso terapéutico , Astrocitoma/diagnóstico por imagen , Astrocitoma/tratamiento farmacológico , Astrocitoma/patología , Astrocitoma/radioterapia , Biopsia , Neoplasias Encefálicas/diagnóstico por imagen , Neoplasias Encefálicas/tratamiento farmacológico , Neoplasias Encefálicas/mortalidad , Neoplasias Encefálicas/patología , Neoplasias Encefálicas/radioterapia , Carmustina/administración & dosificación , Carmustina/uso terapéutico , Progresión de la Enfermedad , Femenino , Glioblastoma/diagnóstico por imagen , Glioblastoma/tratamiento farmacológico , Glioblastoma/patología , Glioblastoma/radioterapia , Glioma/tratamiento farmacológico , Glioma/mortalidad , Glioma/radioterapia , Humanos , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Análisis de Supervivencia , Tomografía Computarizada por Rayos XRESUMEN
PURPOSE: Based on early clinical evidence of potential mucosal protection by granulocyte-macrophage colony stimulating factor (GM-CSF), the Radiation Therapy Oncology Group conducted a double-blind, placebo-controlled, randomized study to test the efficacy and safety of GM-CSF in reducing the severity and duration of mucosal injury and pain (mucositis) associated with curative radiotherapy (RT) in head-and-neck cancer patients. METHODS AND MATERIALS: Eligible patients included those with head-and-neck cancer with radiation ports encompassing >50% of oral cavity and/or oropharynx. Standard RT ports were used to cover the primary tumor and regional lymphatics at risk in standard fractionation to 60-70 Gy. Concurrent cisplatin chemotherapy was allowed. Patients were randomized to receive subcutaneous injection of GM-CSF 250 microg/m2 or placebo 3 times a week. Mucosal reaction was assessed during the course of RT using the National Cancer Institute Common Toxicity Criteria and the protocol-specific scoring system. RESULTS: Between October 2000 and September 2002, 130 patients from 36 institutions were accrued. Nine patients (7%) were excluded from the analysis, 3 as a result of drug unavailability. More than 80% of the patients participated in the quality-of-life endpoint of this study. The GM-CSF did not cause any increase in toxicity compared with placebo. There was no statistically significant difference in the average mean mucositis score in the GM-CSF and placebo arms by a t test (p = 0.4006). CONCLUSION: This placebo-controlled, randomized study demonstrated no significant effect of GM-CSF given concurrently compared with placebo in reducing the severity or duration of RT-induced mucositis in patients undergoing definitive RT for head-and-neck cancer.
Asunto(s)
Factor Estimulante de Colonias de Granulocitos y Macrófagos/uso terapéutico , Neoplasias de Cabeza y Cuello/radioterapia , Traumatismos por Radiación/prevención & control , Protectores contra Radiación/uso terapéutico , Estomatitis/prevención & control , Adulto , Anciano , Anciano de 80 o más Años , Método Doble Ciego , Femenino , Factor Estimulante de Colonias de Granulocitos y Macrófagos/efectos adversos , Humanos , Masculino , Persona de Mediana Edad , Mucosa Bucal/efectos de los fármacos , Mucosa Bucal/efectos de la radiación , Estudios Prospectivos , Protectores contra Radiación/efectos adversos , Estomatitis/etiologíaRESUMEN
PURPOSE: The specific aim of this study was to evaluate outcome differences by gender and partner status for patients treated on Radiation Therapy Oncology Group (RTOG) protocol 97-14. METHODS AND MATERIALS: RTOG 97-14 randomized patients with metastatic breast or prostate cancer to bone to receive 8 Gy in 1 fraction or 30 Gy in 10 fractions. Retreatment rates and overall survival were made based upon gender, marital status, and Karnofsky Performance Status (KPS). The cumulative incidence method was used to estimate retreatment time at 36 months from enrollment, and Gray's test was used to test for treatment differences within the same groupings. Marital status, gender, KPS, and treatment were variables tested in a univariate Cox model evaluating the time to retreatment. RESULTS: Married men and women and single women receiving 30 Gy had significantly longer time to retreatment, p = 0.0067, p = 0.0052, and p = 0.0009 respectively. We failed to show a difference in retreatment rates over time in single men receiving either 30 Gy or 8 Gy. Univariate analysis of the entire group determined patients receiving 30 Gy in 10 fractions significantly less likely to receive retreatment, p < 0.0001, with a trend toward single patients less likely to be re-treated, p = 0.07. CONCLUSION: Non-disease-related variables, such as social support, might influence the results of clinical trials with subjective endpoints such as retreatment rates. The statistically nonsignificant difference in the 36-month retreatment rates observed in single male patients receiving 8 Gy may be a result of inadequate social support systems in place to facilitate additional care. Patients receiving 8 Gy in a single fraction had significantly higher retreatment rates compared with patients receiving 30 Gy in 10 fractions.
Asunto(s)
Neoplasias Óseas/radioterapia , Neoplasias Óseas/secundario , Neoplasias de la Mama/radioterapia , Neoplasias de la Próstata/radioterapia , Persona Soltera , Adulto , Anciano , Anciano de 80 o más Años , Neoplasias Óseas/mortalidad , Neoplasias de la Mama/mortalidad , Femenino , Humanos , Estado de Ejecución de Karnofsky , Masculino , Estado Civil , Persona de Mediana Edad , Dimensión del Dolor , Cuidados Paliativos , Modelos de Riesgos Proporcionales , Neoplasias de la Próstata/mortalidad , Dosificación Radioterapéutica , Retratamiento/estadística & datos numéricos , Factores Sexuales , Resultado del TratamientoRESUMEN
Radiation therapy is an important curative modality in the treatment of patients with head and neck cancer. However, radiation-induced changes in the oral cavity, such as xerostomia and mucositis, are among the most debilitating treatment sequelae experienced by patients undergoing radiation therapy, and attempts at ameliorating these side effects have been poor at best. Pilocarpine has been approved for post-radiation xerostomia, and the effect of its use during radiation therapy on salivary flow, xerostomia, mucositis, and quality of life (QOL) was assessed in a phase III study conducted by the Radiation Therapy Oncology Group (RTOG 97-09). In total, 245 evaluable patients were randomized to pilocarpine or placebo. Selected patients were required to have > or = 50% of the volume of the major salivary glands receive > or = 50Gy; to agree to provide stimulated and unstimulated samples of saliva (measured in g) before treatment, at the end of treatment, and 3 and 6 months after completion of radiation therapy; and to complete the University of Washington Head and Neck Symptom Scale. Following the completion of radiation therapy, the average unstimulated salivary flow was statistically greater in the pilocarpine group, whereas no difference was noted following parotid stimulation. There was no effect on the amelioration of mucositis. The results of the QOL scales did not reveal any significant difference between the pilocarpine and placebo groups with regard to xerostomia and mucositis. The significant difference in unstimulated salivary flow supports the concomitant use of oral pilocarpine to decrease radiation-associated xerostomia. However, the absent correlation between improved salivary flow and QOL scores is of some concern (though not a new finding) and may be related to the existence of comorbidities and the lack of effect on mucositis.
Asunto(s)
Neoplasias de Cabeza y Cuello/radioterapia , Agonistas Muscarínicos/uso terapéutico , Pilocarpina/uso terapéutico , Traumatismos por Radiación/tratamiento farmacológico , Estomatitis/prevención & control , Xerostomía/prevención & control , Femenino , Humanos , Masculino , Persona de Mediana Edad , Calidad de Vida , Salivación/efectos de los fármacos , Estomatitis/etiología , Xerostomía/etiologíaRESUMEN
BACKGROUND AND PURPOSE: To review the data from an implantable radiation dosimetry system used in a clinical setting and to examine correlations between dosimeter readings and potential causative error sources. MATERIALS AND METHODS: MOSFET (metal oxide semiconductor field effect transistor) based encapsulated dosimeters were evaluated in a phantom (in vitro) and in a study with 18 patients. The dosimeters were placed in the gross tumor volume or in collateral normal tissue. Predicted dose values were established by imaging the dosimeters in the planning CTs. RESULTS: The in vitro study confirmed that bounding cumulative errors due to setup, planning, and machine output within a +/-5% level is achievable. In patients, it was found that deviations from the targeted dose often exceeded the 5% level. CONCLUSIONS: The use of an implantable dosimeter system could provide an effective empiric check on the dose delivered at depth. Such a tool may have value for institutional quality assurance, as well as for therapy delivered to individual patients.
Asunto(s)
Fantasmas de Imagen , Radiometría/instrumentación , Dosificación Radioterapéutica , Semiconductores , Relación Dosis-Respuesta en la Radiación , Humanos , Proyectos PilotoRESUMEN
BACKGROUND: Radiation therapy is effective in palliating pain from bone metastases. We investigated whether 8 Gy delivered in a single treatment fraction provides pain and narcotic relief that is equivalent to that of the standard treatment course of 30 Gy delivered in 10 treatment fractions over 2 weeks. METHODS: A prospective, phase III randomized study of palliative radiation therapy was conducted for patients with breast or prostate cancer who had one to three sites of painful bone metastases and moderate to severe pain. Patients were randomly assigned to 8 Gy in one treatment fraction (8-Gy arm) or to 30 Gy in 10 treatment fractions (30-Gy arm). Pain relief at 3 months after randomization was evaluated with the Brief Pain Inventory. The Wilcoxon-Mann-Whitney test was used to compare response to treatment in terms of pain and narcotic relief between the two arms and for each stratification variable. All statistical comparisons were two-sided. RESULTS: There were 455 patients in the 8-Gy arm and 443 in the 30-Gy arm; pretreatment characteristics were equally balanced between arms. Grade 2-4 acute toxicity was more frequent in the 30-Gy arm (17%) than in the 8-Gy arm (10%) (difference = 7%, 95% CI = 3% to 12%; P = .002). Late toxicity was rare (4%) in both arms. The overall response rate was 66%. Complete and partial response rates were 15% and 50%, respectively, in the 8-Gy arm compared with 18% and 48% in the 30-Gy arm (P = .6). At 3 months, 33% of all patients no longer required narcotic medications. The incidence of subsequent pathologic fracture was 5% for the 8-Gy arm and 4% for the 30-Gy arm. The retreatment rate was statistically significantly higher in the 8-Gy arm (18%) than in the 30-Gy arm (9%) (P < .001). CONCLUSIONS: Both regimens were equivalent in terms of pain and narcotic relief at 3 months and were well tolerated with few adverse effects. The 8-Gy arm had a higher rate of re-treatment but had less acute toxicity than the 30-Gy arm.
Asunto(s)
Neoplasias Óseas/radioterapia , Neoplasias Óseas/secundario , Neoplasias de la Mama/patología , Fraccionamiento de la Dosis de Radiación , Dolor/radioterapia , Cuidados Paliativos/métodos , Neoplasias de la Próstata/patología , Adulto , Anciano , Analgésicos Opioides/administración & dosificación , Neoplasias Óseas/complicaciones , Femenino , Fracturas Espontáneas/etiología , Fracturas Espontáneas/prevención & control , Humanos , Masculino , Persona de Mediana Edad , Dolor/etiología , Estudios Prospectivos , Proyectos de Investigación , Retratamiento , Encuestas y Cuestionarios , Resultado del TratamientoAsunto(s)
Traumatismos por Radiación/patología , Radioterapia Conformacional/efectos adversos , Xerostomía/etiología , Fraccionamiento de la Dosis de Radiación , Neoplasias de Cabeza y Cuello/radioterapia , Humanos , Glándula Parótida/efectos de la radiación , Traumatismos por Radiación/prevención & control , Planificación de la Radioterapia Asistida por Computador , Radioterapia Conformacional/métodos , Glándulas Salivales/efectos de la radiación , Salivación/efectos de la radiación , Xerostomía/patologíaRESUMEN
PURPOSE: An implantable radiation dosimeter has been developed to monitor dose delivered at depth in patients undergoing external beam therapy. A clinical pilot study was conducted to test the safety, efficacy, and utility of the device. METHODS AND MATERIALS: Ten patients, all with unresectable malignant disease, were enrolled to assess implantation risk and movement of the device in the body and to compare the in vivo measured dose to the value predicted by the treatment planning system software. RESULTS: Migration of the sensor away from the point of original placement was noted in only 1 patient (due to unconsolidated host tissue) and no adverse events were recorded during the implantation procedure or thereafter. Daily dose measurements were recorded successfully for all sensors in all patients. Variance between measured and predicted dose values was reported as a frequency of error at the > or =5% and > or =8% levels. The error frequency at the > or =8% level was as high as 47%, 29%, and 21% for lung, prostate, and rectal tumors, respectively. CONCLUSIONS: The implantable dosimeter was found to be safe and effective in measuring dose at depth. There are many factors that can influence delivered dose, and the implantable dosimeter measures the net effect of these factors. The daily sensor readings provide a new tool for rigorous treatment quality assurance.
Asunto(s)
Neoplasias/radioterapia , Dosificación Radioterapéutica , Humanos , Neoplasias Pulmonares/radioterapia , Masculino , Proyectos Piloto , Neoplasias de la Próstata/radioterapia , Radiometría/instrumentación , Neoplasias del Recto/radioterapia , Transistores ElectrónicosRESUMEN
An implantable radiation dosimeter for use with external beam therapy has been developed and tested both in vitro and in canines. The device uses a MOSFET dosimeter and is polled telemetrically every day during the course of therapy. The device is designed for permanent implantation and also acts as a radiographic fiducial marker. Ten dogs (companion animals) that presented with spontaneous, malignant tumors were enrolled in the study and received an implant in the tumor CTV. Three dogs received an additional implant in collateral normal tissue. Radiation therapy plans were created for the animals and they were treated with roughly 300 cGy daily fractions until completion of the prescribed cumulative dose. The primary endpoints of the study were to record any adverse events due to sensor placement and to monitor any movement away from the point of placement. No adverse events were recorded. Unacceptable device migration was experienced in two subjects and a retention mechanism was developed to prevent movement in the future. Daily dose readings were successfully acquired in all subjects. A rigorous in vitro calibration methodology has been developed to ensure that the implanted devices maintain an accuracy of +/-3.5% relative to an ionization chamber standard. The authors believe that an implantable radiation dosimeter is a practical and powerful tool that fosters individualized patient QA on a daily basis.
Asunto(s)
Análisis de Falla de Equipo , Prótesis e Implantes , Garantía de la Calidad de Atención de Salud/métodos , Radiometría/instrumentación , Radioterapia Asistida por Computador/instrumentación , Radioterapia Conformacional/instrumentación , Telemetría/instrumentación , Animales , Perros , Cuerpos Extraños/diagnóstico por imagen , Cuerpos Extraños/etiología , Falla de Prótesis , Radiografía , Radiometría/efectos adversos , Radiometría/métodos , Dosificación Radioterapéutica , Radioterapia Asistida por Computador/efectos adversos , Radioterapia Conformacional/métodos , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Telemetría/efectos adversos , Telemetría/métodosRESUMEN
Xerostomia is commonly measured and graded using objective measures of major salivary gland output and observer-rated toxicity grading. The separation between the different grades is somewhat ambiguous in the current toxicity grading systems. We propose a new grading system based primarily on the functional deficits associated with xerostomia. Salivary flow rates have been added as a criterion to the grading system, notwithstanding the weak correlation reported in most studies between the symptoms and objective functional measures. In addition to the observer-rated toxicity grading, recording of patient-reported quality of life, using validated instruments, is encouraged.